Nature Communications (May 2021)
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer
- Aritro Nath,
- Patrick A. Cosgrove,
- Hoda Mirsafian,
- Elizabeth L. Christie,
- Lance Pflieger,
- Benjamin Copeland,
- Sumana Majumdar,
- Mihaela C. Cristea,
- Ernest S. Han,
- Stephen J. Lee,
- Edward W. Wang,
- Sian Fereday,
- Nadia Traficante,
- Ravi Salgia,
- Theresa Werner,
- Adam L. Cohen,
- Philip Moos,
- Jeffrey T. Chang,
- David D. L. Bowtell,
- Andrea H. Bild
Affiliations
- Aritro Nath
- Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center
- Patrick A. Cosgrove
- Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center
- Hoda Mirsafian
- Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center
- Elizabeth L. Christie
- Peter MacCallum Cancer Centre
- Lance Pflieger
- Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center
- Benjamin Copeland
- Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center
- Sumana Majumdar
- Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center
- Mihaela C. Cristea
- Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center
- Ernest S. Han
- Division of Gynecologic Oncology, Department of Surgery, City of Hope
- Stephen J. Lee
- Division of Gynecologic Oncology, Department of Surgery, City of Hope
- Edward W. Wang
- Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center
- Sian Fereday
- Peter MacCallum Cancer Centre
- Nadia Traficante
- Peter MacCallum Cancer Centre
- Ravi Salgia
- Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center
- Theresa Werner
- Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah
- Adam L. Cohen
- Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah
- Philip Moos
- Department of Pharmacology and Toxicology, University of Utah
- Jeffrey T. Chang
- Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston
- David D. L. Bowtell
- Peter MacCallum Cancer Centre
- Andrea H. Bild
- Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center
- DOI
- https://doi.org/10.1038/s41467-021-23171-3
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 16
Abstract
High-grade serous ovarian cancer (HGSOC) is prone to developing resistance to treatment. Here, the authors use single-cell RNA-seq and an analysis of archetypes, and find that shifts in metabolism and proliferation are associated with the response to treatment and clonal heterogeneity in HGSOC.
